When did Haemonetics report Q3 2026 earnings?

Haemonetics (HAE) reported Q3 2026 earnings on February 5, 2026 before market open.

What were Haemonetics's Q3 2026 revenue and EPS?

Haemonetics reported revenue of $339.0M and eps of $1.31 for Q3 2026.

Did Haemonetics beat estimates in Q3 2026?

Revenue beat the consensus estimate of $331.9M by $7.1M. EPS beat the consensus estimate of $1.27 by $0.04.

How did Haemonetics's Q3 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue declined 2.7% from $348.5M a year earlier and eps grew 10.1% from $1.19.

Where can I find Haemonetics's Q3 2026 SEC filings?

You can read the 8-K earnings release (0000313143-26-000009) and the 10-Q periodic report (0000313143-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.

Haemonetics HAE Q3 2026 earnings

Reported February 5, 2026 · Before market open

Revenue$339.0MBeat by $7.1M

EPS$1.31Beat by $0.04

Revenue estimate$331.9M

EPS estimate$1.27

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$327.9M

EPS estimate$1.07

Financials

Q3 2026

Income statement

See full

Revenue$339.0M-2.7%

Gross profit$202.4M+4.6%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$363.4M+13.3%

Total debt$1.2B0.0%

Total equity$911.5M+0.5%

Total assets$2.5B-1.6%

Cash flow

See full

Operating cash flow$93.6M+114%

CapEx$6.3M-25.7%

Free cash flow$87.2M+148%

Valuation & ratios

Valuation

as of 12/27/25

See full

Market cap$3.75B-4.3%

Enterprise value$4.61B-4.4%

P/E21.4×-8.8×

P/S2.8×0.0×

Profitability

See full

Gross margin59.4%+6.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin23.4%+16.2pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.3×0.0×

Current ratio1.7×-2.2×

Segments

By geography

See full

Europe$48.3M+9.3%

Asia$23.0M-10.0%

Rest of Asia$23.0M-10.0%

Other$1.8M-63.3%

Other Countryor Region$1.8M-63.3%

By segment

See full

Hospital$143.5M-0.3%

Plasma$138.9M+3.5%

Blood Center$56.6M-19.6%

By product

See full

Hospital$287.0M-0.3%

Plasma$138.9M+3.5%

Blood Center$113.1M-19.6%

Versus estimates

Revenue

Q4 2026$346.4MBeat by $9.5M

Q3 2026$339.0MBeat by $7.1M

Q2 2026$327.3MMiss by $2.5M Q1 2026$321.4MBeat by $1.4M Q4 2025$330.6MBeat by $18.1M Q3 2025$348.5MMiss by $5.9M

Diluted EPS

Q4 2026$1.29Beat by $0.01

Q3 2026$1.31Beat by $0.04

Q2 2026$1.27Beat by $0.15 Q1 2026$1.10Beat by $0.09 Q4 2025$1.24Beat by $0.02 Q3 2025$1.19Beat by $0.01

Ask the moment Haemonetics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Haemonetics report Q3 2026 earnings?: Haemonetics (HAE) reported Q3 2026 earnings on February 5, 2026 before market open.
What were Haemonetics's Q3 2026 revenue and EPS?: Haemonetics reported revenue of $339.0M and eps of $1.31 for Q3 2026.
Did Haemonetics beat estimates in Q3 2026?: Revenue beat the consensus estimate of $331.9M by $7.1M. EPS beat the consensus estimate of $1.27 by $0.04.
How did Haemonetics's Q3 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue declined 2.7% from $348.5M a year earlier and eps grew 10.1% from $1.19.
Where can I find Haemonetics's Q3 2026 SEC filings?: You can read the 8-K earnings release (0000313143-26-000009) and the 10-Q periodic report (0000313143-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.